BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21786095)

  • 1. Role of ¹¹C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.
    Bertagna F; Abuhilal M; Bosio G; Simeone C; Rossini P; Pizzocaro C; Orlando E; Finamanti M; Biasiotto G; Rodella C; Cosciani Cunico S; Giubbini R
    Jpn J Radiol; 2011 Jul; 29(6):394-404. PubMed ID: 21786095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
    Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
    World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
    Chondrogiannis S; Marzola MC; Ferretti A; Maffione AM; Rampin L; Grassetto G; Nanni C; Colletti PM; Rubello D
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1356-64. PubMed ID: 23670521
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
    J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
    Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
    Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
    Breeuwsma AJ; Pruim J; van den Bergh AC; Leliveld AM; Nijman RJ; Dierckx RA; de Jong IJ
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):160-4. PubMed ID: 19783375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
    Rinnab L; Mottaghy FM; Blumstein NM; Reske SN; Hautmann RE; Hohl K; Möller P; Wiegel T; Kuefer R; Gschwend JE
    BJU Int; 2007 Oct; 100(4):786-93. PubMed ID: 17822459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Coradeschi E; Bettinardi V; Gianolli L; Scattoni V; Cozzarini C; Di Muzio N; Rigatti P; Fazio F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.
    Pelosi E; Arena V; Skanjeti A; Pirro V; Douroukas A; Pupi A; Mancini M
    Radiol Med; 2008 Sep; 113(6):895-904. PubMed ID: 18414809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with
    Sobol I; Zaid HB; Haloi R; Mynderse LA; Froemming AT; Lowe VJ; Davis BJ; Kwon ED; Karnes RJ
    J Urol; 2017 Jan; 197(1):129-134. PubMed ID: 27449262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
    Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
    Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.